A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.
-
- STATUS
- Recruiting
-
- participants needed
- 10
Summary
The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD as defined by the Hanifin and Rajka criteria for AD History of AD for 1 year. AD involvement of 550% treatable body surface area at screening and at baseline Procedures include labs, skin swabs, biopsies, EKG, subject questionnaires (excluding scalp).
Details
| Condition | Medical Research |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03725722 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.